UCSF Awarded Nearly $8.4M for CRISPR_SCD001 Gene Editing Trial

UCSF Awarded Nearly $8.4M for CRISPR_SCD001 Gene Editing Trial

300829

UCSF Awarded Nearly $8.4M for CRISPR_SCD001 Gene Editing Trial

The University of California, San Francisco (UCSF) has been awarded $8.39 million to fund a Phase 1/2 clinical trial of CRISPR_SCD001, the first non-viral and CRISPR-Cas9-based gene editing therapy for sickle cell disease (SCD). Researchers will use the gene-editing technology to attempt to correct a genetic mutation in the blood stem cells of patients with severe SCD. The grant comes from the California Institute for Regenerative Medicine or CIRM, which was created by the state’s residents…

You must be logged in to read/download the full post.